Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    • News

  • Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    • News

  • EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    • News

  • RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    • News

  • BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    • News

  • AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    • News

  • Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    • News

  • Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    • News

  • FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    • News

  • Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    • News

Karst backs Aussie small cap following hugely successful pharma strategy

  • In News
  • April 26, 2021
  • Alfred Chan
Karst backs Aussie small cap following hugely successful pharma strategy

Leading fund manager Karst Peak Capital has secured a significant interest in a little-known Aussie pharmaceuticals research company, following the significant success they experienced with a large holding of Avita Medical.

Originally based in Hong Kong but now also with an office in Sydney, Karst’s investment focus includes the healthcare, biotech and pharmaceuticals industry which turned heads last week when the fund secured a 8.90% stake in Pharmaxis (ASX: PXS) for $3.21 million.

Raising eyebrows in the medical investor community was the fact the investment was made via private Placement at $0.08 per share which was higher than the last traded price at the time. Furthermore, it was noted that Pharmaxis was well capitalised and has approximately $20m cash in the bank after the placement with a revenue stream from their mannitol products, putting the Company in a healthy position.

Also as part of the Placement, BVF Partners LP invested a further $800k to maintain its shareholding in Pharmaxis at 19.5%.

Interestingly, Pharmaxis is indirectly networked to one of Karst’s very successful investments – Avita Medical, of which Karst Peak held a 14.9% stake in 2018 when AVH shares were trading around $0.07 each. Prior to the onset of COVID-19, AVH shares traded as high as $16.30 per share in February 2020 before Avita redomiciling to the United States in June 2020.

The flagship product at Avita Medical responsible for the commercial explosion was RECELL, the commercial product developed from ‘Spray-on-Skin’ which was invented by the Company’s founder, Professor Fiona Wood AM. As RECELL sales grew and Avita expanded internationally, building on Wood’s research, she took a step back from corporate operation to focus on medical research where her work is responsible for saving thousands of lives around the world.

Pharmaxis’ primary research focuses on the compound PXS-5505 which targets myelofibrosis, a rare form of cancer, however on 1 April 2021 the Company confirmed that Professor Wood is heading research into their other lead compound PXS-6302. This second discovery has shown promising pre‐clinical results in skin scarring models. Critically, the application of compound PXS-6302 has the potential to inhibit the enzymes responsible for scar tissue formation during the healing process.

While RECELL has the ability to regenerate skin after burns or trauma, the world-first trials of PXS-6302 have the potential to stop scars forming altogether. Professor Wood notes scar-less healing is the vision that has motivated our work in the field over many decades.

Although clinical trials of PXS-6302 are still in the early stages of recruitment, it is understandable why Karst believes Professor Wood has the midas touch given the success they have achieved by backing her in the past.

Pharmaxis welcomes investors to register for updates on their latest developments and industry research by joining their mailing list here.

 

*Owners of this website are PXS shareholders

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
  •  
  •  
  •  
  •  
  • avita medical
  • BVF Partners
  • fiona wood
  • Karst
  • karst peak capital
  • medtech
  • pharma research
  • pharmaceuticals
  • pharmaxis
  • pxs
  • spray on skin
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.